- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01364402
Prevention of Contrast Induced Nephropathy by Erythropoietin
Prevention of Contrast Induced Nephropathy by Erythropoietin in Patients With Diabetes Mellitus and eGFR<60 ml/Min/1.73m2 Undergoing Percutaneous Coronary Intervention
This ia a prospective, randomized, double blind, placebo controlled trial. patients schedule for primary PCI or elective PCI will randomly allocated to receive either a single dose of EPO (Recormon, Roche, Epoetin beta) or saline intravenously before PCI.
The investigators assume that the incidence rate of CIN will be significantly lower in the EPO group compared to placebo. In addition, EPO administration will result in a decrease of infarct size.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Radiological procedures utilizing intravascular contrast media are being widely applied for both diagnostic and therapeutic purposes. This has resulted in the increasing incidence of procedure-related contrast-induced nephropathy (CIN), which was found to be associated with poor outcome including higher in-hospital mortality rates. Therefore, finding ways to prevent CIN is a valuable clinical and research goal. However, there are no current methods for efficient and cost-effective prevention CIN. Erythropoietin (EPO) has been shown to elicit tissue-protective effects in various experimental models and few clinical studies of acute kidney injury (AKI). Therefore, this prospective, randomized, double blind, placebo controlled trial aim to evaluate, for the first time, the effectiveness of EPO in the prevention of CIN after percutaneous coronary intervention (PCI).
The potential reno-protective effect of EPO is expected to reduce the incidence of the third leading cause of hospital-acquired acute kidney injury. The above together with a cardio-protective effect of EPO is expected to reduce patient's morbidity, mortality and the high health cost associated with CIN treatment.
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Lilach Shema-Didi, RN, MPH
- Telefonnummer: 972-507887538
- E-post: lilach_01@yahoo.com
Studera Kontakt Backup
- Namn: Lilach Shema-Didi, RN, MPH
- E-post: Lilach.Shema-Didi@naharia.health.gov.il
Studieorter
-
-
-
Nahariya, Israel
- Rekrytering
- Western Galilee Hospital
-
Kontakt:
- Shaul Atar, MD
- E-post: shaul.atar@naharia.health.gov.il
-
Kontakt:
- Batya Kristal, MD
- E-post: batya.kristal@naharia.health.gov.il
-
Huvudutredare:
- Shaul Atar, MD
-
Huvudutredare:
- Batya Kristal, MD
-
Underutredare:
- Lilach Shema-Didi, RN, MPH
-
Underutredare:
- Irith Weissman, MD
-
Underutredare:
- Ronit Geron, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Over 18 years of age.
- Diabetic patients.
- eGFR < 60 ml/min/1.73m2.
- Scheduled for primary or elective PCI.
Exclusion Criteria:
- Non diabetic patients.
- Patients with eGFR ≥ 60 ml/min/1.73m2.
- Chronic renal replacement therapy.
- Subject with active malignancy.
- Subject with any known history of seizure disorders.
- Subject with polycythemia.
- Uncontrolled hypertension.
- Known allergy or hypersensitivity to EPO.
- Use of EPO 1 week prior to randomization.
- Use of long acting EPO (CERA) during 1 month prior to randomization.
- Use of NAC or bicarbonate during 3 days prior to randomization.
- Contrast media exposure during the last 7 days before randomization.
- Pregnant or lactating women.
- Participation in other clinical trial.
- Refusal or inability to give informed consent due to mental or physical state.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Placebo-jämförare: Placebo
|
normal saline intravenously
Andra namn:
|
Experimentell: Erythropoietin
|
50,000U intravenously
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Incidence of Contrast Induced Nephropathy(CIN)
Tidsram: 1-3 days after exposure to contrast media
|
1-3 days after exposure to contrast media
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Enzymatic infarct size
Tidsram: 6h and 12 h after exposure to contrast media
|
Will be measured by Troponin and CK
|
6h and 12 h after exposure to contrast media
|
Hospital length of stay
Tidsram: participants will be followed for the duration of hospital stay, an expected average of 3 days
|
participants will be followed for the duration of hospital stay, an expected average of 3 days
|
|
Renal replacement therapy
Tidsram: participants will be followed after PCI procedure till discharge, an expected average of 1-2 days
|
participants will be followed after PCI procedure till discharge, an expected average of 1-2 days
|
|
Hospital mortality
Tidsram: participants will be followed after PCI procedure till discharge, an expected average of 1-2 days
|
participants will be followed after PCI procedure till discharge, an expected average of 1-2 days
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Shaul Atar, MD, Western Galilee Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- EPO1
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Epoetin beta
-
Bristol-Myers SquibbInte längre tillgänglig
-
Changhai HospitalAvslutadKronisk HBV-infektion | DrogabstinensKina
-
Medical University of ViennaOkänd
-
Medical University of ViennaAllergy Centre Vienna WestOkänd
-
Virginia Commonwealth UniversityNRG OncologyRekryteringProstatacancerFörenta staterna
-
Hoffmann-La RocheAvslutad
-
PfizerAvslutad
-
Hospital de Clinicas de Porto AlegreOswaldo Cruz Foundation; Rio Grande do Sul State Health Department - SES...AvslutadJämförelse av effektiviteten av två formuleringar av epoetin hos patienter som genomgår hemodialys
-
Hoffmann-La RocheAvslutadAnemiKorea, Republiken av
-
MegalabsAzidus LaboratoriesHar inte rekryterat ännuAnemi av kronisk njursjukdomUruguay